Comparison of Amphotericin B Lipid Complex (ABLC) vs. AmBisome in the Treatment of Suspected or Documented Fungal Infections in Patients with Leukemia

References

• Mirsky HS, Cuttner J. Fungal infection in acute leukemia. Center 1972; 30: 348–352
   Google Scholar
• Nosari A, Oreste P., Muti G., et al. Fungal infections in hematologic neoplasms: Autopsy findings. Blood 1996; 88: 2874a
   Web of Science ®Google Scholar
• Walsh T, Lee J, Lecciones J, et al. Emphiric therapy wi5h amphotericin B in febrile granulocytopenic patients. Reviews of Infectious Diseases 1991; 13: 496–503
   PubMedGoogle Scholar
• Burch PA, Karp JE, Merz WG, et al. Favorable outcome of invasive aspergillosis in patients with acute leukemia. Journal of Clinical Oncology 1987; 5: 1985–93
   PubMed Web of Science ®Google Scholar
• Aisner J, Wiernik PH, Schimpff S. Treatment of invasive aspergillosis: relation of early diagnosis and treatment to response. Annals of Internal Medicine 1977; 86: 539–43
   PubMed Web of Science ®Google Scholar
• Sarosi G. Amphotericin B: still the gold standard for antifungal therapy. Postgrad Med 1990; 88: 151–66
   PubMed Web of Science ®Google Scholar
• Andstrom E, Ringden O, Remberger M, et al. Safety and efficacy of liposomal amphotericin B in allogeneic bone marrow transplant recipients. Mycoses 1996; 39: 185–93
   PubMed Web of Science ®Google Scholar
• Bohme A, Hoelzerm D. Liposomal amphotericin B as early empiric antimycotic therapy of pneumonia in granulocytopenic patients. Mycoses 1996; 39: 419–26
   PubMed Web of Science ®Google Scholar
• Goldstone A., O'Driscoll A. Early Ambisome in febrile neutropenia in patients with haematological disorders. Bone Marrow Transplantation 1994; 14: S15–7
   PubMed Web of Science ®Google Scholar
• Kruger W, Stockshlader M, Russman B, et al. Experience with liposomal Amphotericin-B in 60 patients undergoing high-dose therapy and bone marrow or peripheral blood stem cell transplantation. British Journal of Haematology 1995; 91: 684–90
   PubMed Web of Science ®Google Scholar
• Lister J. Amphotericin B Lipid Complex (Abelcet) in the treatment of invasive mycoses: the North American experience. European Journal of Haematology 1996; 57: 18–23
   Google Scholar
• Mehta J, Kelsey S, Chu P, et al. Amphotericin B lipid complex (ABLC) for the treatment of confirmed or presumed fungal infections in immunocompromised patients with hematologic malignancies. Bone Marrow Transplantation 1997; 20: 39–43
   PubMed Web of Science ®Google Scholar
• Sharkey P, Graybill J, Johnson E, et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clinical Infectious Diseases 1996; 22: 315–21
   PubMed Web of Science ®Google Scholar
• Ng TT, Denning D. Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Evaluation of United Kingdom compassionate use data. Archives of Internal Medicine 1995; 155: 1093–8
   PubMed Web of Science ®Google Scholar
• Mills W, Chopra R, Linch D, Goldstone A. Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-center experience of 133 episodes in 116 patients. British Journal of Haematology 1994; 98: 711–8
   Google Scholar
• Prentice H, Hann I, Herbrecht R, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. British Journal of Haematology 1997; 98: 711–8
   PubMed Web of Science ®Google Scholar
• Fleming R., Estey E, Kantarjian H., et al. Invasive aspergillosis during induction therapy for acute leukemia: Predisposing and prognostic factors. Blood 1906; 88: 319a
   Google Scholar
• Janknegt R, Van Etten EWM, De Marie S. Lipid formulations of amphotericin B. Curr Opinion Infect Dis 1996; 9: 403–6
   Web of Science ®Google Scholar
• Hiemenz J, Walsh T. Lipid formulations of amphotericin B: recent progress and future directions. Clinical Infectious Diseases 1996; 22: S133–44
   Web of Science ®Google Scholar
• Ringden O, Andstrom E, Remberger M, et al. Safety of liposomal amphotericin B (AmBisome) in 187 transplant recipients treated with cyclosporin. Bone Marrow Transplantation 1994; 14: S10–4
   PubMed Web of Science ®Google Scholar
• Hiemenz J, Lister J, Anaissie EJ, et al. Emergency-use amphotericin B lipid complex (ABLC) in the treatment of patients with aspergillosis: historical-control comparison with amphotericin B. Blood 1995; 86: 3383a
   Web of Science ®Google Scholar
• Tollemar J, Ringden O. Lipid formulations of amphotericin B: less toxicity but at what economic cost?. Drug Safety 1995; 13: 207–218
   PubMed Web of Science ®Google Scholar
• Gilbert D, Moellering RC, Sande M. The Sanford guide to antimicrobial therapy. 28th edn. Austria. Antimicrobial therapy, Vienna 1999; 78
   Google Scholar